Catherine Owen Adams

Catherine Owen Adams, CEO of Acadia Pharmaceuticals, talks regulatory setbacks, EU vs FDA differences, and strategy for rare-disease drugs. Ed Ludlow, Bloomberg Tech co-anchor, breaks down Nvidia’s $1 trillion AI-chip forecast, customer mix, and the Vera Rubin hardware push. Multiple short segments cover chip demand, inference platforms, and competitive pressures.

Catherine Owen Adams, CEO of Acadia Pharmaceuticals, leads the charge in developing therapies for rare neurological diseases. She discusses the company's groundbreaking FDA-approved treatments for Parkinson's psychosis and Rett syndrome. Catherine highlights the challenges posed by cuts to U.S. research funding and advocates for policies that prioritize small biotechs. She emphasizes the importance of patient support services and collaboration with advocacy groups to ensure access to innovative therapies for underserved communities.